vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and MOVADO GROUP INC (MOV). Click either name above to swap in a different company.
MOVADO GROUP INC is the larger business by last-quarter revenue ($186.1M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 5.1%, a 8.2% gap on every dollar of revenue. On growth, MOVADO GROUP INC posted the faster year-over-year revenue change (1.9% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $11.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 2.9%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Movado is a luxury American watch brand originally founded in 1881 in Switzerland. Movado means "movement" in Esperanto. The watches are known for their signature metallic dot at 12 o'clock and minimalist style; the company is best known for its Museum Watch.
AMPH vs MOV — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $186.1M |
| Net Profit | $24.4M | $9.6M |
| Gross Margin | 46.8% | 54.3% |
| Operating Margin | 19.4% | 6.3% |
| Net Margin | 13.3% | 5.1% |
| Revenue YoY | -1.8% | 1.9% |
| Net Profit YoY | -35.7% | 89.8% |
| EPS (diluted) | $0.51 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $186.1M | ||
| Q3 25 | $191.8M | $161.8M | ||
| Q2 25 | $174.4M | $131.8M | ||
| Q1 25 | $170.5M | $181.5M | ||
| Q4 24 | $186.5M | $180.5M | ||
| Q3 24 | $191.2M | $157.0M | ||
| Q2 24 | $182.4M | $134.4M | ||
| Q1 24 | $171.8M | $175.8M |
| Q4 25 | $24.4M | $9.6M | ||
| Q3 25 | $17.4M | $3.0M | ||
| Q2 25 | $31.0M | $1.4M | ||
| Q1 25 | $25.3M | $8.1M | ||
| Q4 24 | $38.0M | $4.8M | ||
| Q3 24 | $40.4M | $3.5M | ||
| Q2 24 | $37.9M | $2.0M | ||
| Q1 24 | $43.2M | $9.8M |
| Q4 25 | 46.8% | 54.3% | ||
| Q3 25 | 51.4% | 54.1% | ||
| Q2 25 | 49.6% | 54.1% | ||
| Q1 25 | 50.0% | 54.2% | ||
| Q4 24 | 46.5% | 53.5% | ||
| Q3 24 | 53.3% | 54.3% | ||
| Q2 24 | 52.2% | 54.3% | ||
| Q1 24 | 52.4% | 53.5% |
| Q4 25 | 19.4% | 6.3% | ||
| Q3 25 | 13.2% | 2.5% | ||
| Q2 25 | 24.2% | 0.2% | ||
| Q1 25 | 21.9% | 5.1% | ||
| Q4 24 | 24.2% | 3.3% | ||
| Q3 24 | 29.8% | 1.7% | ||
| Q2 24 | 30.3% | 1.6% | ||
| Q1 24 | 27.9% | 6.1% |
| Q4 25 | 13.3% | 5.1% | ||
| Q3 25 | 9.0% | 1.8% | ||
| Q2 25 | 17.8% | 1.1% | ||
| Q1 25 | 14.8% | 4.4% | ||
| Q4 24 | 20.4% | 2.7% | ||
| Q3 24 | 21.1% | 2.2% | ||
| Q2 24 | 20.8% | 1.5% | ||
| Q1 24 | 25.1% | 5.6% |
| Q4 25 | $0.51 | $0.42 | ||
| Q3 25 | $0.37 | $0.13 | ||
| Q2 25 | $0.64 | $0.06 | ||
| Q1 25 | $0.51 | $0.36 | ||
| Q4 24 | $0.74 | $0.21 | ||
| Q3 24 | $0.78 | $0.15 | ||
| Q2 24 | $0.73 | $0.09 | ||
| Q1 24 | $0.81 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $183.9M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $497.5M |
| Total Assets | $1.6B | $751.9M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $183.9M | ||
| Q3 25 | $276.2M | $180.5M | ||
| Q2 25 | $231.8M | $203.1M | ||
| Q1 25 | $236.9M | $208.5M | ||
| Q4 24 | $221.6M | $181.5M | ||
| Q3 24 | $250.5M | $198.3M | ||
| Q2 24 | $217.8M | $225.4M | ||
| Q1 24 | $289.6M | $262.1M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $497.5M | ||
| Q3 25 | $776.7M | $489.9M | ||
| Q2 25 | $757.5M | $493.2M | ||
| Q1 25 | $751.3M | $481.3M | ||
| Q4 24 | $732.3M | $491.3M | ||
| Q3 24 | $727.7M | $492.0M | ||
| Q2 24 | $713.3M | $489.6M | ||
| Q1 24 | $672.4M | $505.9M |
| Q4 25 | $1.6B | $751.9M | ||
| Q3 25 | $1.7B | $748.7M | ||
| Q2 25 | $1.6B | $747.2M | ||
| Q1 25 | $1.6B | $729.2M | ||
| Q4 24 | $1.6B | $747.2M | ||
| Q3 24 | $1.5B | $742.5M | ||
| Q2 24 | $1.5B | $736.0M | ||
| Q1 24 | $1.6B | $756.5M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $12.3M |
| Free Cash FlowOCF − Capex | $24.6M | $11.6M |
| FCF MarginFCF / Revenue | 13.4% | 6.2% |
| Capex IntensityCapex / Revenue | 4.5% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $35.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $12.3M | ||
| Q3 25 | $52.6M | $-3.8M | ||
| Q2 25 | $35.6M | $-7.2M | ||
| Q1 25 | $35.1M | $39.1M | ||
| Q4 24 | $29.0M | $-4.7M | ||
| Q3 24 | $60.0M | $-17.8M | ||
| Q2 24 | $69.1M | $-18.1M | ||
| Q1 24 | $55.3M | $69.4M |
| Q4 25 | $24.6M | $11.6M | ||
| Q3 25 | $47.2M | $-5.1M | ||
| Q2 25 | $25.0M | $-8.7M | ||
| Q1 25 | $24.4M | $37.5M | ||
| Q4 24 | $16.6M | $-7.2M | ||
| Q3 24 | $46.2M | $-20.1M | ||
| Q2 24 | $63.1M | $-19.7M | ||
| Q1 24 | $46.5M | $67.8M |
| Q4 25 | 13.4% | 6.2% | ||
| Q3 25 | 24.6% | -3.1% | ||
| Q2 25 | 14.3% | -6.6% | ||
| Q1 25 | 14.3% | 20.7% | ||
| Q4 24 | 8.9% | -4.0% | ||
| Q3 24 | 24.1% | -12.8% | ||
| Q2 24 | 34.6% | -14.7% | ||
| Q1 24 | 27.1% | 38.6% |
| Q4 25 | 4.5% | 0.4% | ||
| Q3 25 | 2.8% | 0.8% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 0.9% | ||
| Q4 24 | 6.7% | 1.4% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 5.1% | 0.9% |
| Q4 25 | 1.35× | 1.28× | ||
| Q3 25 | 3.03× | -1.27× | ||
| Q2 25 | 1.15× | -5.08× | ||
| Q1 25 | 1.39× | 4.86× | ||
| Q4 24 | 0.76× | -0.98× | ||
| Q3 24 | 1.48× | -5.14× | ||
| Q2 24 | 1.82× | -8.97× | ||
| Q1 24 | 1.28× | 7.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MOV
| Other | $81.4M | 44% |
| Owned Brands Category | $46.0M | 25% |
| Sales Channel Directly To Consumer | $35.3M | 19% |
| Company Stores | $23.4M | 13% |
